Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 165 versus MICONAZOLE 7.
FULVICIN P/G 165 vs MICONAZOLE 7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Griseofulvin binds to and disrupts microtubule function by inhibiting spindle formation and mitosis in dermatophytes, leading to inhibition of fungal cell division.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
165 mg orally once daily.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Terminal elimination half-life is approximately 9-24 hours; dependent on formulation and absorption rate. Steady-state achieved within 4-5 days.
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Primarily renal excretion of metabolites; <1% excreted unchanged. Biliary/fecal elimination accounts for ~30% of metabolites.
Primarily fecal (~50%) and renal (~<1% unchanged)
Category C
Category A/B
Antifungal
Antifungal